» Articles » PMID: 37527529

Membranous Nephropathy

Overview
Journal J Bras Nefrol
Specialty Nephrology
Date 2023 Aug 1
PMID 37527529
Authors
Affiliations
Soon will be listed here.
Abstract

Membranous nephropathy is a glomerulopathy, which main affected target is the podocyte, and has consequences on the glomerular basement membrane. It is more common in adults, especially over 50 years of age. The clinical presentation is nephrotic syndrome, but many cases can evolve with asymptomatic non-nephrotic proteinuria. The mechanism consists of the deposition of immune complexes in the subepithelial space of the glomerular capillary loop with subsequent activation of the complement system. Great advances in the identification of potential target antigens have occurred in the last twenty years, and the main one is the protein "M-type phospholipase-A2 receptor" (PLA2R) with the circulating anti-PLA2R antibody, which makes it possible to evaluate the activity and prognosis of this nephropathy. This route of injury corresponds to approximately 70% to 80% of cases of membranous nephropathy characterized as primary. In the last 10 years, several other potential target antigens have been identified. This review proposes to present clinical, etiopathogenic and therapeutic aspects of membranous nephropathy in a didactic manner, including cases that occur during kidney transplantation.

Citing Articles

Safranal Ameliorates Renal Damage, Inflammation, and Podocyte Injury in Membranous Nephropathy via SIRT/NF-κB Signalling.

Bao Y, Ge Y, Wang Z, Wang H, Wang Q, Yuan J Curr Med Sci. 2025; .

PMID: 40035996 DOI: 10.1007/s11596-025-00020-8.


Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review.

Gentile M, Manenti L J Clin Med. 2025; 14(3).

PMID: 39941374 PMC: 11818541. DOI: 10.3390/jcm14030702.


Different Dosage Regimens of Rituximab in Primary Membranous Nephropathy Treatment: A Systematic Review.

Yu Y, Xu R, Li Z, Wan Q Int J Nephrol Renovasc Dis. 2024; 17:265-273.

PMID: 39493295 PMC: 11531282. DOI: 10.2147/IJNRD.S489455.

References
1.
Honda K, Horita S, Toki D, Taneda S, Nitta K, Hattori M . De novo membranous nephropathy and antibody-mediated rejection in transplanted kidney. Clin Transplant. 2010; 25(2):191-200. DOI: 10.1111/j.1399-0012.2010.01213.x. View

2.
Dabade T, Grande J, Norby S, Fervenza F, Cosio F . Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant. 2008; 8(6):1318-22. DOI: 10.1111/j.1600-6143.2008.02237.x. View

3.
Kerjaschki D, Farquhar M . Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med. 1983; 157(2):667-86. PMC: 2186920. DOI: 10.1084/jem.157.2.667. View

4.
El-Zoghby Z, Grande J, Fraile M, Norby S, Fervenza F, Cosio F . Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant. 2009; 9(12):2800-7. DOI: 10.1111/j.1600-6143.2009.02851.x. View

5.
. Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl (2011). 2014; 2(2):186-197. PMC: 4089709. DOI: 10.1038/kisup.2012.20. View